Market Performance
Mineralys Therapeutics (MLYS)
Closed 2.22 % lower at USD 21.47 during the 24‑hour period ending 06:02 AM Central Europe, Friday 23 March 2026.
Current trading volume: USD 17.1 million.
Outstanding shares: 88.5 million.
Market capitalization: USD 1.9 billion.
200‑day simple moving average: USD 27.45.
52‑week high: USD 47.65 (12 November 2025).
52‑week low: USD 20.12 (16 October 2026).
Year‑to‑date performance (since end of February 2025): -28.23 %.
Peer Performance (last 24 hours)
Ticker Change Current price Market cap P/E ratio RH +6.91 % USD 140.15 USD 2.3 bn 21.17 BELFA +2.99 % USD 161.69 USD 2.3 bn 41.47 HRMY -1.01 % USD 36.03 USD 2.3 bn 12.59 FTRE +5.62 % USD 23.92 USD 2.3 bn – UFPT -0.42 % USD 297.33 USD 2.3 bn 31.53
Company Overview
Mineralys Therapeutics, Inc. is a clinical‑stage biopharmaceutical firm headquartered in Wayne, United States. The company focuses on developing aldosterone synthase inhibitors (ASI) to treat conditions associated with excess aldosterone, notably uncontrolled hypertension. Mineralys is listed on the Nasdaq exchange and conducts its operations within the Health Care sector.
Key corporate milestones:
- IPO: Scheduled for 9 February 2023.
- Website: www.mineralystx.com
The company’s financial and operational metrics are available through standard regulatory filings and investor presentations.
